Table 2

Response after ONYX-015 injection related to study variables

Response was assessed by radiological scanning in 22 patients and by physical exam in 2 patients.

Patient groupTotal no.No. of PatientsPb
CRaPRMRSDPD
p53 gene sequence
Mutant12223320.017
Wild type700043
Not evaluable501022
Neutralizing antibodies (baseline)
Positive14122720.76
Negative1011125
Tumor diameter (maximum)
<3 cm9020340.34
≥3 cm1521363
CD4 cell count (cells/μl)
<50014211551.00
≥500701132
Not evaluable301110
Treatment regimen
Standard19222670.71
Hyperfractionated501130
  • a CR, complete response; PR, partial response; MR, minor response; SD, stable disease; PD, progressive disease.

  • b P based on comparison of tumors demonstrating antitumor activity (CR, PR, MR) versus no activity (SD, PD) for each evaluable subgroup (Fisher’s exact test).